MedPath

Rilematovir

Generic Name
Rilematovir
Drug Type
Small Molecule
Chemical Formula
C21H20ClF3N4O3S
CAS Number
1383450-81-4
Unique Ingredient Identifier
NQ99E8OH3P

Overview

Rilematovir is under investigation in clinical trial NCT04056611 (Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2021/12/13
Phase 1
Completed
2021/07/27
Phase 2
Terminated
2020/10/12
Phase 3
Terminated
2020/04/02
Phase 1
Terminated
2020/01/09
N/A
NO_LONGER_AVAILABLE
2019/09/16
Phase 1
Completed
2018/09/04
Phase 2
Terminated
2016/12/26
Phase 1
Completed
2016/10/26
Phase 1
Completed
2016/04/06
Phase 1
Completed

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.